Latest Business Development News

Page 6 of 38
First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Berkeley Energia reported a $8.7 million net loss for FY2026 while pushing forward with its Salamanca uranium project and maiden critical minerals resource at Conchas. The company continues a $1.25 billion ICSID arbitration claim against Spain over permitting delays.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.
Ada Torres
Ada Torres
28 Aug 2026
Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.
Ada Torres
Ada Torres
27 Aug 2026
Sierra Nevada Gold (ASX: SNX) has completed a $12.85 million capital raise to fund an aggressive Phase 2 drilling campaign at its As Safra Copper-Gold Project in Saudi Arabia, supported by strong institutional backing.
Maxwell Dee
Maxwell Dee
26 Aug 2026
Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.
Ada Torres
Ada Torres
26 Aug 2026
Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.
Ada Torres
Ada Torres
25 Aug 2026
Jcurve Solutions (ASX:JCS) posted a significant financial turnaround in FY2026, with revenue climbing 16.3% to $13.28 million and normalised EBITDA more than doubling to $1.88 million, underpinned by disciplined cost control and recurring revenue growth.
Sophie Babbage
Sophie Babbage
25 Aug 2026
XPON Technologies (ASX: XPN) posted a $1.1 million positive EBITDA in FY26 on 38% revenue growth, shedding Alpha Digital and selling its Google Marketing business to focus on its Wondaris AI platform.
Sophie Babbage
Sophie Babbage
25 Aug 2026
Electro Optic Systems (ASX:EOS) reported a record first half in 2026 with revenue soaring 283% to A$168.8 million, driven by the MARSS acquisition and expanding defence contracts. The order book jumped 84% to A$846 million, underpinning a bullish outlook amid a global defence spending surge.
Victor Sage
Victor Sage
25 Aug 2026
Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.
Sophie Babbage
Sophie Babbage
25 Aug 2026

Browse the archive

Full archive